About Vico
Vico is a company based in Leiden (Netherlands) founded in 2019 by Judith Van Deutekom and Gail Mandel.. Vico has raised $103.3 million across 3 funding rounds from investors including EQT, Eurazeo and Idinvest Partners. Vico offers products and services including VO659 and ASO Platform. Vico operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Leiden, Netherlands
- Founders Judith Van Deutekom, Gail Mandel
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vico Therapeutics B.V.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$103.3 M (USD)
in 3 rounds
-
Latest Funding Round
$12.3 M (USD), Series B
Jun 24, 2024
-
Investors
EQT
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vico
Vico offers a comprehensive portfolio of products and services, including VO659 and ASO Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets CAG repeat expansion to reduce mutant proteins in neurological diseases.
Enables precision targeting of genetic mutations for rare disorders.
Unlock access to complete
Unlock access to complete
Funding Insights of Vico
Vico has successfully raised a total of $103.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12.3 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $12.3M
-
First Round
First Round
(29 Jul 2020)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2024 | Amount | Series B - Vico | Valuation | Kurma Partners , Ackermans & van Haaren | |
| Jan, 2024 | Amount | Series B - Vico | Valuation | Ackermans & van Haaren , Droia Ventures | |
| Jul, 2020 | Amount | Series A - Vico | Valuation | Life Sciences Partners , Kurma Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vico
Vico has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, Eurazeo and Idinvest Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seroba Lifesciences is focused on life sciences venture capital investments.
|
Founded Year | Domain | Location | |
|
Biotech startups are funded through venture capital in life sciences.
|
Founded Year | Domain | Location | |
|
Droia Ventures is focused on investing in drug development companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vico
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vico
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vico Comparisons
Competitors of Vico
Vico operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vico
Frequently Asked Questions about Vico
When was Vico founded?
Vico was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is Vico located?
Vico is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Is Vico a funded company?
Vico is a funded company, having raised a total of $103.3M across 3 funding rounds to date. The company's 1st funding round was a Series A of $31M, raised on Jul 29, 2020.
What does Vico do?
Vico was founded in 2019 in Leiden, Netherlands, within the biotechnology sector. Antisense oligonucleotide therapies are designed using the VICOMER platform to target RNA in genetic neurological disorders. Conditions addressed include Rett syndrome, Alzheimers disease, Huntingtons disease, and others. The lead program, VO659, is advanced for polyglutamine-related diseases such as spinocerebellar ataxia types 3 and 1, along with Huntingtons disease. Operations focus on therapeutic development for unmet needs in neurology.
Who are the top competitors of Vico?
Vico's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Vico offer?
Vico offers VO659 and ASO Platform.
Who are Vico's investors?
Vico has 11 investors. Key investors include EQT, Eurazeo, Idinvest Partners, Kurma Partners, and Ackermans & van Haaren.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.